PRODUCT LITERATURE

Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting

---

An extended-release (ER) subcutaneously injectable formulation of the first-generation 5-HT3 receptor antagonist granisetron is now available in the USA (Sustol), where it is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy
regimens in adults. Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drugdelivery
system to allow prolonged granisetron release. Primary endpoint data from phase III studies after an initial cycle of chemotherapy indicate that, when used as part of an antiemetic regimen, granisetronERinjection ismore effective than intravenous ondansetron in preventing delayed CINV following highly emetogenic chemotherapy (HEC); is noninferior to intravenous palonosetron in preventing both acute CINV following MEC or HEC and delayed CINV following MEC; and is similar, but not superior, to palonosetron in
preventing delayed CINV following HEC

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Granon
Vomiting
Granisetron Extended-Release Injection
Nausea

Specific Detail Info

DOI : 10.1007/s40265-016-0664-2

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment